Sign In
Buy ACXP
$1.75
-0.0500 (-2.78%)
At Close: Jun 03, 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2023 Earnings Call Transcript
04:28pm, Tuesday, 14'th Nov 2023
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Robert Shawah - CFO David Luci - President & CEO Robert DeLuccia - Executi
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
07:01am, Tuesday, 14'th Nov 2023
STATEN ISLAND, N.Y. , Nov. 14, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary efficacy endpoint of the Clinical Cure rat
Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update
07:01am, Wednesday, 25'th Oct 2023
STATEN ISLAND, N.Y. , Oct. 25, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences
07:01am, Thursday, 19'th Oct 2023
Three scientific posters highlighting novel anti-virulence pharmacologic properties of oral ibezapolstat for C. difficile Infection; effects on toxin production, biofilm and the gut microbiome A podi
Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023
07:01am, Tuesday, 22'nd Aug 2023
STATEN ISLAND, N.Y. , Aug. 22, 2023 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiot
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023
07:01am, Tuesday, 20'th Jun 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference. STATEN ISLAND, N.Y.
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2022 Earnings Call Transcript
02:20pm, Thursday, 16'th Mar 2023
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q4 2022 Earnings Conference Call March 16, 2023 8:00 AM ET Company Participants Robert Shawah - Co-Founder & Chief Financial Officer David Luci - President &
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
08:01am, Monday, 16'th Jan 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND,
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2022 Earnings Call Transcript
11:14am, Monday, 14'th Nov 2022
Start Time: 08:30 January 1, 0000 8:49 AM ET Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 AM ET Company Participants David Luci - President and
STATEN ISLAND, N.Y. , Nov. 1, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q2 2022 Results - Earnings Call Transcript
11:53am, Tuesday, 16'th Aug 2022
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2022 Earnings Conference Call August 16, 2022 8:30 AM ET Company Participants Robert Shawah - CFO David Luci - CEO Conference Call Participants Jim Molloy
STATEN ISLAND, N.Y. , Aug. 4, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibioti
Acurx Pharmaceuticals, Inc.'s (ACXP) CEO David Luci on Q1 2022 Results - Earnings Call Transcript
03:58pm, Wednesday, 11'th May 2022
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Rob Shawah - Chief Financial Officer David Luci - President and Chief Executive
STATEN ISLAND, N.Y. , April 29, 2022 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibi
